{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:55:04Z","timestamp":1785876904780,"version":"3.56.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/15\/2023-5901"],"award-info":[{"award-number":["EMDR\/SG\/15\/2023-5901"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRP-2023-5901"],"award-info":[{"award-number":["IIRP-2023-5901"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbadis.2026.168321","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:47:10Z","timestamp":1781048830000},"page":"168321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Involvement of immunomodulators in the development of cancer vaccines"],"prefix":"10.1016","volume":"1872","author":[{"given":"Roshni","family":"Bibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Swayamsiddhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subham","family":"Saishree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mmanan","family":"Sobti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmith","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koustav","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbadis.2026.168321_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbadis.2026.168321_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102429","article-title":"Therapeutic cancer vaccines: from biological mechanisms and engineering to ongoing clinical trials","volume":"109","author":"Sobhani","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbadis.2026.168321_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"issue":"9","key":"10.1016\/j.bbadis.2026.168321_bb0020","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1172\/JCI80008","article-title":"Tumor neoantigens: building a framework for personalized cancer immunotherapy","volume":"125","author":"Gubin","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bbadis.2026.168321_bb0025","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168321_bb0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0035","author":"Cancer Research Institute"},{"issue":"11","key":"10.1016\/j.bbadis.2026.168321_bb0040","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nri3904","article-title":"\u03b3\u03b4 T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"20","key":"10.1016\/j.bbadis.2026.168321_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011256","article-title":"Cancer vaccines: recent insights and future directions","volume":"25","author":"Malacopol","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0050","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s12672-024-01638-1","article-title":"Revolutionizing cancer treatment: the rise of personalized immunotherapies","volume":"15","author":"Fayyaz","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1501010","article-title":"Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy","volume":"14","author":"Imani","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"7662","key":"10.1016\/j.bbadis.2026.168321_bb0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2026.168321_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104981","article-title":"Clinical efficacy and challenges of cancer-testis antigen vaccines in advanced solid tumors: a systematic review and meta-analysis","volume":"216","author":"Jiang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0070","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbadis.2026.168321_bb0075","series-title":"American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting","article-title":"State-of-the-art advancements on cancer vaccines and biomarkers","volume":"vol. 44(3)","author":"Strum","year":"2024"},{"issue":"7","key":"10.1016\/j.bbadis.2026.168321_bb0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.635337","article-title":"Developmental landscape of potential vaccine candidates based on viral vector for prophylaxis of COVID-19","volume":"8","author":"Bezbaruah","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"18","key":"10.1016\/j.bbadis.2026.168321_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71187","article-title":"Promising cancer vaccine for glioblastoma therapy: a focus on mRNA vaccine","volume":"14","author":"Barati","year":"2025","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0095","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"Med (N. Y.)"},{"key":"10.1016\/j.bbadis.2026.168321_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: target antigens, vaccine platforms and preclinical models","volume":"101","author":"Ruzzi","year":"2025","journal-title":"Mol. Asp. Med."},{"issue":"9","key":"10.1016\/j.bbadis.2026.168321_bb0105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146956","article-title":"Vaccines for immunoprevention of cancer","volume":"131","author":"Enokida","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2026.168321_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.641307","article-title":"Moving on from sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer","volume":"12","author":"Sutherland","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168321_bb0115","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41416-023-02327-6","article-title":"Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response","volume":"129","author":"P\u00e9rez-Ba\u00f1os","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"24","key":"10.1016\/j.bbadis.2026.168321_bb0120","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2026.168321_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8653489","article-title":"Immunomodulatory effects of drugs for effective cancer immunotherapy","volume":"2018","author":"Matsushita","year":"2018","journal-title":"J. Oncol."},{"issue":"7637","key":"10.1016\/j.bbadis.2026.168321_bb0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bbadis.2026.168321_bb0135","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.181.5.1755","article-title":"Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4","volume":"181","author":"Jacobson","year":"1995","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol. Biomed."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168321_bb0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamaoncol.2024.5356","article-title":"Deep learning model for predicting immunotherapy response in advanced non-small cell lung cancer","volume":"11","author":"Rakaee","year":"2025","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0150","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-025-03396-6","article-title":"A novel pH-sensitive nanoparticles encapsulating anti-PD-1 antibody and MDK-siRNA overcome immune checkpoint blockade resistance in HCC via reshaping immunosuppressive TME","volume":"44","author":"Xu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168321_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400512","article-title":"Immunomodulatory peptides for tumor treatment","volume":"14","author":"Song","year":"2025","journal-title":"Adv. Healthc. Mater."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168321_bb0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4110\/in.2013.13.5.177","article-title":"Nanoparticle-based vaccine delivery for cancer immunotherapy","volume":"13","author":"Park","year":"2013","journal-title":"Immune Netw."},{"key":"10.1016\/j.bbadis.2026.168321_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","author":"Grippin","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbadis.2026.168321_bb0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","article-title":"Personalized neoantigen cancer vaccines: current progression, challenges and a bright future","volume":"24","author":"Wu","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168321_bb0185","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0190","article-title":"Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168321_bb0195","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"CheckMate 816 Investigators. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2026.168321_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1227833","article-title":"Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy","volume":"14","author":"Chakraborty","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-09535-5","article-title":"Intratumoral expression of IL-12 and CD40 ligand (CD154) from plasmids generates antitumor responses that eliminate tumoral T regs","volume":"15","author":"Ho","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2026.168321_bb0210","article-title":"Role of GM-CSF in lung balance and disease","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168321_bb0215","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14712598.2024.2357714","article-title":"Next-generation CD40 agonists for cancer immunotherapy","volume":"24","author":"Andersson","year":"2024","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"39","key":"10.1016\/j.bbadis.2026.168321_bb0220","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103651118","article-title":"Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response","volume":"118","author":"Ro\u00dfmann","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0225","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12964-024-01680-0","article-title":"STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy","volume":"22","author":"Rezabakhsh","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/cells13010034","article-title":"Emerging immunotherapy approaches for advanced clear cell renal cell carcinoma","volume":"13","author":"Meng","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.bbadis.2026.168321_bb0235","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/vaccines11020394","article-title":"Overcoming suppressive tumor microenvironment by vaccines in solid tumor","volume":"11","author":"Xie","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0240","article-title":"Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment","volume":"16","author":"Feng","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2026.168321_bb0245","article-title":"Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bbadis.2026.168321_bb0250","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/cancers13092018","article-title":"Overcoming the immunosuppressive tumor microenvironment in multiple myeloma","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.bbadis.2026.168321_bb0255","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/j.seminoncol.2012.02.002","article-title":"Strategies to use immune modulators in therapeutic vaccines against cancer","volume":"39","author":"Berzofsky","year":"2012","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0260","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.bbadis.2026.168321_bb0265","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1237327","article-title":"IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay","volume":"5","author":"Weng","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbadis.2026.168321_bb0270","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR family members in costimulation of T cell responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0280","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.bbadis.2026.168321_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005548","article-title":"Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors","volume":"10","author":"Natoli","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbadis.2026.168321_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563383","article-title":"Editorial: beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy","volume":"16","author":"Haramati","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1494206","article-title":"Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation","volume":"15","author":"Hangiu","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168321_bb0300","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/curroncol32040230","article-title":"LAG3, TIM3 and TIGIT: new targets for immunotherapy and potential associations with radiotherapy","volume":"32","author":"Mire\u0219tean","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1541326","article-title":"Advancements and challenges in personalized neoantigen-based cancer vaccines","volume":"19","author":"Singh","year":"2025","journal-title":"Oncol. Rev."},{"issue":"7","key":"10.1016\/j.bbadis.2026.168321_bb0310","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1245\/s10434-025-17281-1","article-title":"The landmark series: therapeutic cancer vaccine strategies for cold tumors","volume":"32","author":"Blair","year":"2025","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168321_bb0315","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168321_bb0320","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168321_bb0325","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41416-023-02181-6","article-title":"Immune checkpoint inhibitor combinations-current and emerging strategies","volume":"128","author":"Walsh","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2026.168321_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1616872","article-title":"New dimensions of PD-1\/PD-L1 inhibitor combination therapy in cancer treatment: current advances and future perspectives","volume":"16","author":"Tong","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0335","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/vaccines13010069","article-title":"Efficacy of anti-cancer immune responses elicited using tumor-targeted IL-2 cytokine and its derivatives in combined preclinical therapies","volume":"13","author":"Balkhi","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.bbadis.2026.168321_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1218082","article-title":"Engineering cytokines for cancer immunotherapy: a systematic review","volume":"14","author":"Fu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0345","article-title":"Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0350","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4062\/biomolther.2023.196","article-title":"Current development status of cytokines for cancer immunotherapy","volume":"32","author":"Song","year":"2024","journal-title":"Biomol. Ther."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0355","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168321_bb0360","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2017.02.028","article-title":"IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer","volume":"145","author":"Felices","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168321_bb0365","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00262-016-1828-3","article-title":"Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands","volume":"65","author":"Klein","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"24","key":"10.1016\/j.bbadis.2026.168321_bb0370","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.3390\/cancers14246091","article-title":"Combination of STING and TLR 7\/8 agonists as vaccine adjuvants for cancer immunotherapy","volume":"14","author":"Bhatnagar","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0375","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cGAS\u2013STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168321_bb0380","doi-asserted-by":"crossref","DOI":"10.1042\/EBC20253006","article-title":"The cGAS-STING pathway in cancer immunity: dual roles, therapeutic strategies, and clinical challenges","volume":"69","author":"Yue","year":"2025","journal-title":"Essays Biochem."},{"key":"10.1016\/j.bbadis.2026.168321_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1482738","article-title":"Targeting STING signaling for the optimal cancer immunotherapy","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168321_bb0390","doi-asserted-by":"crossref","first-page":"292","DOI":"10.18632\/oncotarget.27886","article-title":"Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model","volume":"12","author":"Zaidi","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2026.168321_bb0395","article-title":"Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1594621","article-title":"Advances of oncolytic vaccinia viruses armed with interleukin in tumor therapy","volume":"15","author":"Zha","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0405","article-title":"Advances in preclinical and clinical studies of oncolytic virus combination therapy","volume":"15","author":"Du","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1454183","article-title":"Editorial: recent advances in gene modified immune cells and oncolytic virus for cancer immunotherapy","volume":"15","author":"Yuan","year":"2024","journal-title":"Front. Immunol."},{"issue":"25","key":"10.1016\/j.bbadis.2026.168321_bb0415","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168321_bb0420","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/ph18081086","article-title":"Nanoparticles for cancer immunotherapy: innovations and challenges","volume":"18","author":"Fallatah","year":"2025","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"9","key":"10.1016\/j.bbadis.2026.168321_bb0425","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","article-title":"A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists","volume":"18","author":"Baljon","year":"2024","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.bbadis.2026.168321_bb0430","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/pharmaceutics17020216","article-title":"Cancer vaccines and beyond: the transformative role of nanotechnology in immunotherapy","volume":"17","author":"Delgado-Almenta","year":"2025","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.bbadis.2026.168321_bb0435","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.7150\/thno.112475","article-title":"Nano drug delivery systems for advanced immune checkpoint blockade therapy","volume":"15","author":"Guo","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.bbadis.2026.168321_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2024.1492215","article-title":"Nanomaterial-based cancer immunotherapy: enhancing treatment strategies","volume":"12","author":"Tian","year":"2024","journal-title":"Front. Chem."},{"issue":"12","key":"10.1016\/j.bbadis.2026.168321_bb0445","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw6071","article-title":"A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer","volume":"6","author":"Ni","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0450","doi-asserted-by":"crossref","DOI":"10.1002\/bmm2.12112","article-title":"Nano\/genetically engineered cells for immunotherapy","volume":"3","author":"Shen","year":"2025","journal-title":"BMEMat."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168321_bb0455","doi-asserted-by":"crossref","DOI":"10.1002\/bmm2.12079","article-title":"Regulated cell death-amplified sonodynamic anti-tumor immune nanotherapeutics","volume":"2","author":"Zhou","year":"2024","journal-title":"BMEMat"},{"issue":"2","key":"10.1016\/j.bbadis.2026.168321_bb0460","article-title":"Advanced strategies for combinational immunotherapy of cancer based on polymeric nanomedicines","volume":"2","author":"You","year":"2024","journal-title":"BMEMat"},{"key":"10.1016\/j.bbadis.2026.168321_bb0465","article-title":"Harnessing nanomaterials to precisely regulate the immunosuppressive tumor microenvironment for enhanced immunotherapy","author":"Zhang","year":"2025","journal-title":"BMEMat"},{"key":"10.1016\/j.bbadis.2026.168321_bb0470","doi-asserted-by":"crossref","DOI":"10.1002\/bmm2.70003","article-title":"Designing next-generation immune cell therapies with nanomaterials","author":"Chen","year":"2025","journal-title":"BMEMat"},{"key":"10.1016\/j.bbadis.2026.168321_bb0475","article-title":"Metal coordination-driven assembly of stimulator of interferon genes-activating nanoparticles for tumor chemo-immunotherapy","author":"Zhang","year":"2024","journal-title":"BMEMat"},{"key":"10.1016\/j.bbadis.2026.168321_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1249718","article-title":"TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview","volume":"14","author":"Kayesh","year":"2023","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168321_bb0485","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/cells10051058","article-title":"Enhancing a natural killer: modification of NK cells for cancer immunotherapy","volume":"10","author":"Islam","year":"2021","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.bbadis.2026.168321_bb0490","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2026.168321_bb0495","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1129343","article-title":"Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies","volume":"11","author":"Bhardwaj","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"7963","key":"10.1016\/j.bbadis.2026.168321_bb0500","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2026.168321_bb0505","article-title":"Safety and efficacy of personalized cancer vaccines in combination with immune checkpoint inhibitors in cancer treatment","volume":"11","author":"Liao","year":"2021","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.bbadis.2026.168321_bb0510","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1021\/acs.accounts.0c00456","article-title":"Engineered nanoparticles for cancer vaccination and immunotherapy","volume":"53","author":"Aikins","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bbadis.2026.168321_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1529403","article-title":"Recent advances in novel tumor immunotherapy strategies based on regulating the tumor microenvironment and immune checkpoints","volume":"16","author":"Jing","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbadis.2026.168321_bb0520","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12032-025-02818-x","article-title":"Tumor microenvironment and immunotherapy: from bench to bedside","volume":"42","author":"Sinha","year":"2025","journal-title":"Med. Oncol."},{"issue":"28","key":"10.1016\/j.bbadis.2026.168321_bb0525","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2174\/0115680266321659240906114742","article-title":"PIM kinase inhibitors as novel promising therapeutic scaffolds in cancer therapy","volume":"24","author":"Karati","year":"2024","journal-title":"Curr. Top. Med. Chem."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168321_bb0530","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems","volume":"22","author":"Baryakova","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.bbadis.2026.168321_bb0535","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/cancers17111882","article-title":"Current progress and future perspectives of RNA-based cancer vaccines: a 2025 update","volume":"17","author":"Magoola","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bbadis.2026.168321_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103378","article-title":"Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies","volume":"86","author":"Shah","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0545","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12943-025-02400-z","article-title":"Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions","volume":"24","author":"Mandal","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbadis.2026.168321_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1530541","article-title":"Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions","volume":"15","author":"Ruan","year":"2025","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168321_bb0555","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s12026-024-09483-8","article-title":"The immunosuppressive landscape in tumor microenvironment","volume":"72","author":"Liu","year":"2024","journal-title":"Immunol. Res."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168321_bb0560","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/vaccines4040036","article-title":"The role of myeloid-derived suppressor cells (MDSC) in cancer progression","volume":"4","author":"Umansky","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.bbadis.2026.168321_bb0565","article-title":"Targeting tumor-infiltrating tregs for improved antitumor responses","volume":"15","author":"Qin","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0570","article-title":"Immunocytes in the tumor microenvironment: recent updates and interconnections","volume":"16","author":"Yu","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168321_bb0575","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/0008-5472.CAN-23-2042","article-title":"Targeting tumor heterogeneity with neoantigen-based cancer vaccines","volume":"84","author":"Pounraj","year":"2024","journal-title":"Cancer Res."},{"issue":"Pt 1","key":"10.1016\/j.bbadis.2026.168321_bb0580","article-title":"Prospects and challenges of neoantigen applications in oncology","volume":"143","author":"Shi","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbadis.2026.168321_bb0585","article-title":"Advances and challenges in neoantigen prediction for cancer immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bbadis.2026.168321_bb0590","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/vaccines12121341","article-title":"Challenges and new directions in therapeutic cancer vaccine development","volume":"12","author":"Pan","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.bbadis.2026.168321_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0600","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-024-01628-4","article-title":"Personalized nanovaccines for treating solid cancer metastases","volume":"17","author":"Feng","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.bbadis.2026.168321_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13090900","article-title":"Nanovaccines: innovative advances from design strategies to clinical translation","volume":"13","author":"He","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.bbadis.2026.168321_bb0610","doi-asserted-by":"crossref","DOI":"10.1038\/s44386-025-00029-y","article-title":"Integrating artificial intelligence into small molecule development for precision cancer immunomodulation therapy","volume":"2","author":"Sutanto","year":"2025","journal-title":"npj Drug Discov."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0615","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"4","key":"10.1016\/j.bbadis.2026.168321_bb0620","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011540","article-title":"Gut reactions: harnessing microbial metabolism to fuel next-generation cancer immunotherapy","volume":"13","author":"Almonte","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbadis.2026.168321_bb0625","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184321","article-title":"The gut microbiome and cancer response to checkpoint inhibitors","volume":"135","author":"Gazzaniga","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2026.168321_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1607388","article-title":"Gut microbiota: a promising new target in immune tolerance","volume":"16","author":"Almansour","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bbadis.2026.168321_bb0635","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11912-024-01611-9","article-title":"Talimogene laherparepvec (T-VEC) and emerging intralesional immunotherapies for metastatic melanoma: a review","volume":"26","author":"Kalsi","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bbadis.2026.168321_bb0640","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2025.1666561","article-title":"Epigenetic and metabolic reprogramming via nanotechnology: a synergistic approach to cancer vaccination in lung tumors","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168321_bb0645","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbadis.2026.168321_bb0650","article-title":"Advances in STING pathway modulation for cancer and immunotherapy: a comprehensive review of preclinical and clinical studies (2020-2024)","author":"Shaik","year":"2025","journal-title":"Cancer Biother. Radiopharm."},{"issue":"50","key":"10.1016\/j.bbadis.2026.168321_bb0655","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202402802","article-title":"Optimized fabrication of dendritic mesoporous silica nanoparticles as efficient delivery system for cancer immunotherapy","volume":"20","author":"Godakhindi","year":"2024","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168321_bb0660","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.bbadis.2026.168321_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.02.007","article-title":"\u03b2-Glucan-modified nanoparticles with different particle sizes exhibit different lymphatic targeting efficiencies and adjuvant effects","volume":"14","author":"Guo","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.bbadis.2026.168321_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1505656","article-title":"Focus on gut microbes: new direction in cancer treatment","volume":"15","author":"Liao","year":"2025","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168321_bb0675","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70070","article-title":"The microbiome in cancer","volume":"4","author":"Lin","year":"2025","journal-title":"iMeta"},{"key":"10.1016\/j.bbadis.2026.168321_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1559480","article-title":"Microbiota as diagnostic biomarkers: advancing early cancer detection and personalized therapeutic approaches through microbiome profiling","volume":"16","author":"Eslami","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168321_bb0685","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-472902","article-title":"Gut microbiota in immuno-oncology: a practical guide for medical oncologists with a focus on antibiotics stewardship","volume":"45","author":"Elkrief","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:42:48Z","timestamp":1785876168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443926001845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":136,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0925443926001845"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168321","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involvement of immunomodulators in the development of cancer vaccines","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168321"}}